Horizons ETFs to Launch World’s First Psychedelics-Focused ETF
Ryan Allway January 22nd, 2021 Psychedelics Horizons ETFs Management (Canada) Inc. (“Horizons ETFs“) is pleased to announce that it has filed its final prospectus to launch the Horizons Psychedelic Stock Index ETF (“PSYK“). Units of PSYK have been conditionally approved for listing by the NEO Exchange (“NEO“) and are... Read more
Mydecine Innovations Group Included in First-Ever Psychedelics ETF
Ryan Allway January 22nd, 2021 Psychedelics Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged Traded... Read more
Entheon Biomedical to be Included in First North American Psychedelic ETF
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Revive Therapeutics Included in First Psychedelic Exchange Traded Fund
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Havn Life Sciences Announces Inclusion in First Psychedelic Exchange Traded Fund
Ryan Allway January 22nd, 2021 Psychedelics, Top News VANCOUVER, BC / ACCESSWIRE / January 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will... Read more
MagicMed wendet die Idee des Modells einer Bibliothek für Medikamentenkandidaten auch auf Psychedelika an
Ryan Allway January 20th, 2021 German, Psychedelics Der Psychedelika-Markt wird oft mit Wörtern, wie “aufstrebend”, “aufkeimend” und ähnlichen beschrieben, und obwohl dies sicherlich weitgehend zutrifft, sollten Anleger keinen Moment denken, dass dies alles neu ist. Das Gegenteil ist der Fall. Es gibt eine Vielzahl klinischer und präklinischer Daten, die... Read more
Tryp Therapeutics Invited to Present at “Investing in Psychedelics” Conference
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Empower Clinics Announces First Ever AGORACOM Video Q&A with Shareholders Submitting Questions for Direct Response by CEO Steven McAuley
Ryan Allway January 19th, 2021 Psychedelics EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower“) an integrated healthcare company serving patients through medical clinics in USA and Canada, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA... Read more
Former LifeLabs COO Joins Novamind Leadership Team
Ryan Allway January 19th, 2021 Psychedelics Novamind Inc., (CSE:NM) (“Novamind”) a mental health company specialized in psychedelic medicine, announces the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer. Effective immediately, Mr. Bou-Mansour will assume responsibility for ensuring operational... Read more
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders
Ryan Allway January 19th, 2021 Psychedelics Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into an Exclusive Worldwide License... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )